Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis
- Focus Pharmacodynamics
- Acronyms TBEV POLYGELINE FREE-025 EXT:021
- Sponsors GlaxoSmithKline
- 15 Jan 2018 Planned End Date changed from 7 Apr 2022 to 3 Nov 2021.
- 15 Jan 2018 Planned primary completion date changed from 7 Apr 2022 to 3 Nov 2021.
- 13 Nov 2017 Status changed from recruiting to active, no longer recruiting.